Related Experiment Video
Updated: Sep 24, 2025
Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
Inhibitory role of recombinant neorudin on canine coronary artery thrombosis
Yu-Bin Liu1, Xing-Chen Zhou1, Yun Liu1
1Beijing Institute of Radiation Medicine, Beijing, China.
Insights
Recombinant neorudin (EPR-hirudin, EH) effectively inhibits canine coronary artery thrombosis in a dose-dependent manner. EH also shows reduced bleeding compared to low molecular weight heparin (LMWH).
Area of Science:
- Cardiovascular Pharmacology
- Thrombosis Research
Background:
- Anticoagulant therapy is crucial for managing cardiovascular diseases.
- Thrombosis, particularly in coronary arteries, is a major cause of cardiac events.
- Existing anticoagulants like low molecular weight heparin (LMWH) have associated bleeding risks.
Purpose of the Study:
- To evaluate the antithrombotic efficacy of recombinant neorudin (EPR-hirudin, EH).
- To compare the bleeding profile of EH with LMWH in a canine thrombosis model.
Main Methods:
- A canine model of coronary artery thrombosis was established using Folt's method.
- Intravenous administration of varying doses of EH (0.3, 1.0, 3.0 mg/kg) was employed.
- EH's antithrombotic activity and bleeding parameters were assessed and compared to LMWH.
Main Results:
- EH demonstrated a significant, dose-dependent inhibition of coronary artery thrombosis, with effective rates of 66.7% to 100% (p < 0.05 to p < 0.01).
- EH exhibited a lower bleeding tendency, characterized by shorter bleeding times and reduced blood loss compared to LMWH.
- At equivalent antithrombotic effect intensities, EH showed significantly less bleeding than LMWH (p < 0.05).
Conclusions:
- Recombinant neorudin (EH) is a potent antithrombotic agent effective against coronary artery thrombosis.
- EH presents a potentially safer alternative to LMWH due to its reduced bleeding side effects.
Abstract:
The anticoagulant application is an effective treatment modality for cardiovascular diseases such as coronary heart disease, unstable angina pectoris, and myocardial infarction. In this study, the antithrombotic effect of recombinant neorudin (EPR-hirudin, EH) was evaluated using a canine model of coronary artery thrombosis. A canine model with platelet thrombosis in the left circumferent branch of the coronary artery was designed using Folt's method, and the anti-thrombus activity of EH was investigated. Femoral administration of EH intravenously had a significant dose-dependent inhibitory effect on canine coronary artery thrombosis and the effective rates were 66.7% (p < .05), 83.3% (p < .05), and 100% (p < .01) after injection of 0.3, 1.0, and 3.0 mg/kg EH, respectively. Furthermore, EH demonstrated lower bleeding, with shorter bleeding time and less bleeding loss than low molecular weight heparin (LMWH). Under the similar effect intensity of EH and LMWH (85 IU/kg), the bleeding time of the EH group at 30 min was shorter, and the blood loss at 30-120 min was less than that of LMWH (p < .05 and p < .05-.001, respectively). EH had a significant dose-dependent inhibitory effect in the dose range of 0.3-3.0 mg/kg on the coronary artery thrombosis and lower bleeding side effects than LMWH with a similar antithrombosis effect.
